In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146

Vanissa A. Ong; Amba Lawrence; Peter Timms; Lenka A. Vodstrcil; Sepehr N Tabrizi; Kenneth W Beagley; John A. Allan; Jane S. Hocking; Wilhelmina M Huston

doi:10.1016/j.micinf.2015.09.004

In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146

Vanissa A. Ong
, Amba Lawrence
, Peter Timms
, Lenka A. Vodstrcil
, Sepehr N Tabrizi
, Kenneth W Beagley
, John A. Allan
, Jane S. Hocking
, Wilhelmina M Huston

Research output: Contribution to journal › Article › Research › peer-review

10 Citations (Scopus)

Abstract

The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.

Original language	English
Pages (from-to)	738-744
Number of pages	7
Journal	Microbes and Infection
Volume	17
Issue number	11-12
DOIs	https://doi.org/10.1016/j.micinf.2015.09.004
Publication status	Published - 1 Nov 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chlamydia
Clinical isolate
HtrA
Inhibitor

Access to Document

10.1016/j.micinf.2015.09.004

Cite this

@article{2d015084ca1840f3aeda3e001cb00d46,

title = "In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146",

abstract = "The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.",

keywords = "Chlamydia, Clinical isolate, HtrA, Inhibitor",

author = "Ong, \{Vanissa A.\} and Amba Lawrence and Peter Timms and Vodstrcil, \{Lenka A.\} and Tabrizi, \{Sepehr N\} and Beagley, \{Kenneth W\} and Allan, \{John A.\} and Hocking, \{Jane S.\} and Huston, \{Wilhelmina M\}",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.micinf.2015.09.004",

language = "English",

volume = "17",

pages = "738--744",

journal = "Microbes and Infection",

issn = "1286-4579",

publisher = "Elsevier",

number = "11-12",

}

TY - JOUR

T1 - In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146

AU - Ong, Vanissa A.

AU - Lawrence, Amba

AU - Timms, Peter

AU - Vodstrcil, Lenka A.

AU - Tabrizi, Sepehr N

AU - Beagley, Kenneth W

AU - Allan, John A.

AU - Hocking, Jane S.

AU - Huston, Wilhelmina M

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.

AB - The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.

KW - Chlamydia

KW - Clinical isolate

KW - HtrA

KW - Inhibitor

UR - https://www.scopus.com/pages/publications/84962861976

U2 - 10.1016/j.micinf.2015.09.004

DO - 10.1016/j.micinf.2015.09.004

M3 - Article

AN - SCOPUS:84962861976

SN - 1286-4579

VL - 17

SP - 738

EP - 744

JO - Microbes and Infection

JF - Microbes and Infection

IS - 11-12

ER -

In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this